Entities / Company
Cellectar Biosciences (United States).
company in Madison, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 32
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Cellectar Biosciences is seeking FDA approval for its drug candidate CLR 125, which is designed to treat Triple-Negative Breast Cancer (TNBC).Speculative1 report
-
Cellectar Biosciences signed a multi-year isotope supply agreement with Nusano on June 26, 2025.Speculative2 reports
-
Cellectar Biosciences completed its registration statement with the SEC, with Ladenburg Thalmann serving as the sole bookrunning manager.Speculative2 reports
-
Cellectar Biosciences received a Zacks Rank #2 upgrade reflecting an upward trend in its earnings estimates.Some support1 report
-
Cellectar Biosciences received Breakthrough Therapy Designation from the FDA for its drug iopofosine I 131.Some support3 reports
-
Cellectar Biosciences presented data at the AACR conference on August 27, 2025.Some support1 report
-
Jarrod Longcor was appointed as the chief operating officer of Cellectar Biosciences.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Cellectar Biosciences (United States) this week
News at the entities that move Cellectar Biosciences (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Cellectar Biosciences (United States)
Connections
The 1 strongest of 32, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
FDA provides regulatory guidance and grants designations to Cellectar Biosciences for its drug candidates.
History
Events by the month they beganJune 2026
7 events- Cellectar Biosciences is seeking FDA approval for its drug candidate CLR 125, which is designed to treat Triple-Negative Breast Cancer (TNBC).
- Cellectar Biosciences signed a multi-year isotope supply agreement with Nusano on June 26, 2025.
- Cellectar Biosciences completed its registration statement with the SEC, with Ladenburg Thalmann serving as the sole bookrunning manager.
- Cellectar Biosciences received a Zacks Rank #2 upgrade reflecting an upward trend in its earnings estimates.
- Cellectar Biosciences received Breakthrough Therapy Designation from the FDA for its drug iopofosine I 131.
- Cellectar Biosciences presented data at the AACR conference on August 27, 2025.
- Jarrod Longcor was appointed as the chief operating officer of Cellectar Biosciences.